3 Things In Biotech, March 10: Merck In MS, Bayer's Essure Scrutinized, Tocagen An Orphan

3 Things In Biotech, March 10: Merck In MS, Bayer's Essure Scrutinized, Tocagen An Orphan


Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. News: MKGAY announced findings from its phase 2b study investigating the BCR inhibitor evobrutinib against placebo in patients with relapsing multiple sclerosis.



from Biotech News